FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004262655> ?p ?o ?g. }

• W2004262655 endingPage "2418" @default.
• W2004262655 startingPage "2417" @default.
• W2004262655 abstract "Two manuscripts in this issue of Journal of Clinical Oncology are focused on patients with bone-metastatic castrate-resistant prostate cancer (CRPC) treated with a combination of docetaxel and samarium-ethylenediaminetetramethylenephosphonic acid (Sm-EDTMP). These data are significant from a variety of perspectives, not only because they involve novel combinations of therapy, but also because they potentially lay a foundation for new approaches to treat this common and too often fatal disease. The propensity for prostate cancer to metastasize to bone is well delineated, though debate continues on why this is so. Two recent trials indicate that 84% to 92% of patients with metastatic CRPC have radiographic evidence of bone metastases. By contrast, measureable soft tissue disease (mostly nodal) was present in 39% to 44% of patients. Given the bone-tropic nature of prostate cancer metastases, and the number of men affected by this disease each year, a variety of bone-targeted agents are currently under development. The first bone-targeted agents to gain US Food and Drug Administration approval in the United States for treatment of prostate cancer were two bone-seeking beta particle-emitting radiopharmaceuticals. One of these agents (Strontium [Sr]), is a calcium homolog with a long half-life (50.5 days) and relatively high-energy average beta emission (0.58 MeV). The other is Sm-EDTMP, which binds to the hydroxyapetite crystals in blastic bone lesions and emits a low-energy beta (0.22 MeV) with a relatively short half-life (46 hours). The physical half-life of the isotopes in part determines their toxicity profile. The longer half-life of Sr translates into less reversible myelosuppression than Sm-EDTMP (which is the only notable toxicity encountered with these agents). These agents are approved for the palliative treatment of advanced prostate cancer but have had a relatively limited use. The reasons for limited use are multifactorial. Palliative agents (other than analgesics) have had relatively limited acceptance in the broad oncologic community. Systemic radiopharmaceuticals, even those quite effective in controlling cancer progression, have not been widely adopted by oncologists because of a variety of market forces. Additionally, despite some evidence to the contrary, concerns that systemic radio-isotopes may interfere with subsequent chemotherapy dosing has potentially limited use of these agents. The mechanism of action whereby bone-seeking radiopharmaceuticals exert favorable effects is currently debated. Sr and Sm-EDTMP both target the bone stroma and, as such, may be viewed as part of a new class of oncotherapies termed stromal-targeted therapies. Of note, antiangiogenic agents such as bevacizumab and thalidomide also target stromal rather than cancerous elements. Stromal-targeted agents have the advantage of targeting a relatively homogeneous stroma as compared with genetically heterogeneous cancer cells. Though direct tumoricidal effects are clearly plausible for the bone-targeted radiopharmaceuticals, effects on tumor stromal cells may be equally important. Given the vicious cycle that is hypothesized to occur between epithelial tumors and bone stroma, any effect on one cellular compartment may reverberate in another. For bone-metastatic CRPC, combinations of bone-seeking radiopharmaceuticals and chemotherapy have engendered considerable prior interest. Synergy between these two classes of agents was initially suggested in a small randomized phase II trial published by Tu et al in 2001. This trial used an innovative design in which all patients with bone-predominant metastatic disease were treated with a multi-agent chemotherapy before random assignment between Sr and doxorubicin or doxorubicin alone. Patients intolerant of, or having progression after, two to three cycles of the initial chemotherapy were randomly assigned. This design had the benefit of excluding patients with a poor prognosis, thereby enriching the randomly assigned population in patients more likely to benefit from therapy. The results were impressive in patients treated with combined-modality therapy. Overall survival was nearly 11 months longer (27.7 months) in the Sr plus doxorubicin arm as compared with the doxorubicin-alone arm (16.8 months). By comparison, the enrolled but non–randomly assigned patients (nearly one third of patients in this trial) had an 11.1 month survival, suggesting that rapid progression or intolerance of the multi-agent chemotherapy was a poor prognostic marker. Despite the initial promise of the combining a relatively noneffective chemotherapy (doxorubicin) with an US Food and Drug Administration–approved bone-seeking isotope (Sr), these results have neither been replicated nor expanded to date. The current reports by Morris et al and Fizazi et al provide another attempt to move these concepts forward. The designs of these studies are distinct. The Morris et al study makes the assumption that the docetaxel at 75 mg/m every 3 weeks is the standard of care for patients with bonemetastatic CRPC and attempts to improve on that regimen by adding dose escalated Sm-EDTMP in a repetitive fashion. Repetitive doses of this short–half-life isotope have previously been demonstrated to be well tolerated, but studies in combination with docetaxel at this JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A L VOLUME 27 NUMBER 15 MAY 2" @default.
• W2004262655 created "2016-06-24" @default.
• W2004262655 creator A5073246821 @default.
• W2004262655 date "2009-05-20" @default.
• W2004262655 modified "2023-10-18" @default.
• W2004262655 title "Radiopharmaceutical and Chemotherapy Combinations in Metastatic Castrate-Resistant Prostate Cancer: A New Beginning?" @default.
• W2004262655 cites W1983514189 @default.
• W2004262655 cites W1986170691 @default.
• W2004262655 cites W2045503970 @default.
• W2004262655 cites W2080439368 @default.
• W2004262655 cites W2081463541 @default.
• W2004262655 cites W2120292596 @default.
• W2004262655 cites W2130879093 @default.
• W2004262655 cites W2149547695 @default.
• W2004262655 cites W2158639339 @default.
• W2004262655 doi "https://doi.org/10.1200/jco.2008.21.4460" @default.
• W2004262655 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19364953" @default.
• W2004262655 hasPublicationYear "2009" @default.
• W2004262655 type Work @default.
• W2004262655 sameAs 2004262655 @default.
• W2004262655 citedByCount "7" @default.
• W2004262655 countsByYear W20042626552012 @default.
• W2004262655 countsByYear W20042626552013 @default.
• W2004262655 countsByYear W20042626552015 @default.
• W2004262655 countsByYear W20042626552016 @default.
• W2004262655 crossrefType "journal-article" @default.
• W2004262655 hasAuthorship W2004262655A5073246821 @default.
• W2004262655 hasBestOaLocation W20042626551 @default.
• W2004262655 hasConcept C121608353 @default.
• W2004262655 hasConcept C126322002 @default.
• W2004262655 hasConcept C143998085 @default.
• W2004262655 hasConcept C2776694085 @default.
• W2004262655 hasConcept C2777899217 @default.
• W2004262655 hasConcept C2778971682 @default.
• W2004262655 hasConcept C2780192828 @default.
• W2004262655 hasConcept C2781190966 @default.
• W2004262655 hasConcept C71924100 @default.
• W2004262655 hasConceptScore W2004262655C121608353 @default.
• W2004262655 hasConceptScore W2004262655C126322002 @default.
• W2004262655 hasConceptScore W2004262655C143998085 @default.
• W2004262655 hasConceptScore W2004262655C2776694085 @default.
• W2004262655 hasConceptScore W2004262655C2777899217 @default.
• W2004262655 hasConceptScore W2004262655C2778971682 @default.
• W2004262655 hasConceptScore W2004262655C2780192828 @default.
• W2004262655 hasConceptScore W2004262655C2781190966 @default.
• W2004262655 hasConceptScore W2004262655C71924100 @default.
• W2004262655 hasIssue "15" @default.
• W2004262655 hasLocation W20042626551 @default.
• W2004262655 hasLocation W20042626552 @default.
• W2004262655 hasOpenAccess W2004262655 @default.
• W2004262655 hasPrimaryLocation W20042626551 @default.
• W2004262655 hasRelatedWork W122177069 @default.
• W2004262655 hasRelatedWork W2021751111 @default.
• W2004262655 hasRelatedWork W2094570582 @default.
• W2004262655 hasRelatedWork W2135620818 @default.
• W2004262655 hasRelatedWork W2299690226 @default.
• W2004262655 hasRelatedWork W2408071315 @default.
• W2004262655 hasRelatedWork W2568045406 @default.
• W2004262655 hasRelatedWork W2735900144 @default.
• W2004262655 hasRelatedWork W2776356588 @default.
• W2004262655 hasRelatedWork W2795222586 @default.
• W2004262655 hasVolume "27" @default.
• W2004262655 isParatext "false" @default.
• W2004262655 isRetracted "false" @default.
• W2004262655 magId "2004262655" @default.
• W2004262655 workType "article" @default.